产品详情
产品名称VEGF Conjugated Antibody
来源种属Rabbit
克隆性Monoclonal
应用IF, FC
种属反应性Hu, Ms, Rt
免疫原描述recombinant protein
标记AF荧光素
激发/发射波长AF350: 346nm/442nm
AF405: 401nm/421nm
AF488: 493nm/519nm
AF555: 555nm/565nm
AF594: 591nm/614nm
AF647: 651nm/667nm
AF680: 679nm/702nm
AF750: 749nm/775nm
别名Folliculostellate cell-derived growth factor antibody Glioma-derived endothelial cell mitogen antibody MGC70609 antibody MVCD1 antibody Vascular endothelial growth factor A antibody vascular endothelial growth factor A121 antibody vascular endothelial growth factor A165 antibody vascular endothelial growth factor antibody Vascular permeability factor antibody VEGF A antibody Vegf antibody VEGF-A antibody VEGF120 antibody Vegfa antibody VEGFA_HUMAN antibody VPF antibody
数据库入口号Swiss-Prot#:P15692
Uniprot
P15692
计算分子量43 kDa
配方0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
保存Store at 4˚C in dark for 6 months
应用详情
IF:1:50-1:200
FC: 1:50-1:200
The onset of angiogenesis is believed to be an early event in tumorigenesis and may facilitate tumor progression and metastasis. Several growth factors with angiogenic activity have been described. These include fibroblast growth factors (FGFs), platelet derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). VEGF is a dimeric glycoprotein with structural homology to PDGF. Several variants of VEGF have been described that arise by alternative mRNA splicing. It has been speculated that VEGF may function as a tumor angiogenesis factor in vivo because the expression pattern of VEGF is consistent with a role in embryonic angiogenesis. VEGF mRNA is formed in some primary tumors, VEGF is produced by tumor cell lines in vitro and VEGF mitogenic activity appears to be restricted to endothelial cells. A member of the PDGF receptor family, Flt, has been identified as a high-affinity receptor for VEGF.
如果您使用该产品C48707发表了文章，请通知我们，让我们可以引用您的文献。
et al,Enhancing HepG2 cell apoptosis with a combined nanoparticle delivery of miR-128-3p agomir and Oroxin B: A novel drug delivery approach based on PI3K-AKT and VEGF pathway crosstalk
, (2024),
PMID:
1-2 weeks
